IPSC

Century Therapeutics, Inc. (IPSC) - 10-K Summary

Business Context and Reporting Period

Company: Century Therapeutics, Inc.
Filing Type: Annual Report on Form 10-K
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Century is a biotechnology company developing allogeneic, "off-the-shelf" cell therapies derived from induced pluripotent stem cells (iPSCs). The company focuses on treating Type 1 Diabetes (T1D), autoimmune diseases, and cancer using its proprietary Allo-Evasion™ technology to prevent immune rejection. Key product candidates include CNTY-813 (beta islet cells for T1D), CNTY-308 (CAR-iT cells for B-cell mediated diseases), and CNTY-101 (CAR-iNK cells for autoimmune diseases).

Key Financial Metrics

Note: The 2025 revenue figure is significantly elevated due to the recognition of remaining transaction price from the terminated Bristol-Myers Squibb collaboration. The company has no product sales revenue.

Material Changes vs. Prior Period

• Revenue Recognition: Collaboration revenue increased by $102.6 million year-over-year. This was driven by the termination of the Bristol-Myers Squibb (BMS) collaboration agreement in March 2025, which triggered the recognition of the remaining deferred revenue ($109.2 million) in Q1 2025. No future revenue is expected from this agreement.
• Operating Expenses: Total operating expenses decreased by $18.3 million to $126.4 million. R&D expenses declined by $11.6 million primarily due to a reduction in R&D staff and the completion of a manufacturing campaign under the FCDI collaboration. G&A expenses decreased by $9.2 million due to lower legal fees and a gain on the reduction of contingent consideration liability.
• Impairment Charges: The company recorded a $6.8 million impairment charge on long-lived assets (right-of-use lease assets) in 2025 following a reduction in force and plans to sublease portions of its Philadelphia headquarters. In 2024, a $4.3 million goodwill impairment was recorded.
• Capital Raise: In January 2026 (subsequent to the reporting period), the company completed a private placement raising approximately $126.7 million in net proceeds.

Guidance, Outlook, and Risks

Outlook and Pipeline Status:

• CNTY-813 (T1D): The lead product candidate is in IND-enabling studies. The company anticipates submitting an IND application as early as 2026.
• CNTY-308 (Autoimmune): IND-enabling studies are ongoing. Clinical studies are expected to initiate in 2026 following regulatory authorization.
• CNTY-101 (Autoimmune): Prioritized for clinical development in the CARAMEL Phase 1/2 investigator-sponsored trial (IST), which is currently enrolling and dosing patients. Preliminary data was presented in December 2025.

Liquidity: Management believes that cash, cash equivalents, and investments of $117.1 million as of December 31, 2025, combined with the $126.7 million raised in January 2026, will be sufficient to fund operations into the first quarter of 2029.

Key Risks:

• Development Risk: All product candidates are in preclinical or early clinical stages. Success depends on IND clearance and positive clinical trial results.
• Capital Requirements: The company expects to incur significant losses for the foreseeable future and will require additional financing to fund operations and commercialization.
• Intellectual Property: Reliance on licensed technology from third parties (e.g., FUJIFILM Cellular Dynamics, Inc.) creates risks regarding license termination or disputes.
• Manufacturing: Complexities in scaling iPSC-derived cell therapies and cryopreservation stability pose operational risks.

Investor Verification Checklist

• Revenue Sustainability: Verify that the $109.2 million revenue recognized in 2025 is non-recurring and stems solely from the BMS contract termination, with no expectation of future collaboration revenue from that partner.
• Cash Runway: Confirm the impact of the January 2026 private placement ($126.7 million) on the projected cash runway into Q1 2029.
• IND Timelines: Monitor the progress of IND-enabling studies for CNTY-813 and CNTY-308 to validate the 2026 submission and clinical initiation targets.
• License Agreements: Review the terms of the FCDI agreements (Reprogramming, Differentiation, and Autoimmune licenses) for milestone obligations and termination risks.
• Facility Utilization: Assess the status of the subleasing efforts for the Philadelphia headquarters following the impairment charge and reduction in force.